HER-2 underexpression

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BB-1701 Sensitive: C3 – Early Trials SABCS 2023 - 1 week (New C3) BB-1701 Sensitive : C3 SABCS 2023 - 1wk	BB-1701 Sensitive: C3 – Early Trials SABCS 2023 - 1 week BB-1701 Sensitive : C3 SABCS 2023 - 1 week - (New C3)
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	pyrotinib Sensitive: C3 – Early Trials SABCS 2023 - 1 week (New C3) pyrotinib Sensitive : C3 SABCS 2023 - 1wk	pyrotinib Sensitive: C3 – Early Trials SABCS 2023 - 1 week pyrotinib Sensitive : C3 SABCS 2023 - 1 week - (New C3)
HER-2 underexpression	Hormone Receptor Negative Breast Cancer	HER-2 underexpression	Hormone Receptor Negative Breast Cancer	eribulin mesylate Sensitive: C3 – Early Trials SABCS 2023 - 1 week (New C3) eribulin mesylate Sensitive : C3 SABCS 2023 - 1wk	eribulin mesylate Sensitive: C3 – Early Trials SABCS 2023 - 1 week eribulin mesylate Sensitive : C3 SABCS 2023 - 1 week - (New C3)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B
HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Triple Negative Breast Cancer	HER-2 underexpression	Triple Negative Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Gastric Adenocarcinoma	HER-2 underexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BNT323 Sensitive: C2 – Inclusion Criteria BNT323 Sensitive : C2	BNT323 Sensitive: C2 – Inclusion Criteria BNT323 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 underexpression	Lung Adenocarcinoma	HER-2 underexpression	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	MRG002 Sensitive: C3 – Early Trials MRG002 Sensitive : C3	MRG002 Sensitive: C3 – Early Trials MRG002 Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	BB-1701 Sensitive: C3 – Early Trials BB-1701 Sensitive : C3	BB-1701 Sensitive: C3 – Early Trials BB-1701 Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4	fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy Sensitive : C4
HER-2 underexpression	Ovarian Cancer	HER-2 underexpression	Ovarian Cancer	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D
HER-2 underexpression	Colorectal Cancer	HER-2 underexpression	Colorectal Cancer	SAR446309 Sensitive: D – Preclinical SAR446309 Sensitive : D	SAR446309 Sensitive: D – Preclinical SAR446309 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	trastuzumab-pkrb Sensitive: D – Preclinical trastuzumab-pkrb Sensitive : D	trastuzumab-pkrb Sensitive: D – Preclinical trastuzumab-pkrb Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	trastuzumab + durvalumab Sensitive: D – Preclinical trastuzumab + durvalumab Sensitive : D	trastuzumab + durvalumab Sensitive: D – Preclinical trastuzumab + durvalumab Sensitive : D

HER-2 underexpression

Associations